ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Vutrisiran Reduces Mortality in A.T.T.R. C.M. 10/31/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like natriuresis-guided therapy and echocardiography. Key takeaway: Vutrisiran Reduces Mortality in A.T.T.R. C.M..
Article Links:
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. (ESC heart failure)
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study. (European journal of heart failure)
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. (European journal of heart failure)
Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation. (JACC. Cardiovascular imaging)
Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/
Featured Articles
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41163405
Summary: This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159496
Summary: study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159479
Summary: This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran’s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.
Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41165630
Summary: hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.
Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41166531
Summary: This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat’s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat’s performance in routine clinical practice, confirming its benefits in a broader patient context.
Transcript
Today’s date is October 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.
Article number two. Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-A.H.F. study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.
Article number three. Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The H.E.L.I.O.S.-B trial. This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran’s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.
Article number four. Fully Automatic A.I. hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.
Article number five. Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat’s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat’s performance in routine clinical practice, confirming its benefits in a broader patient context.
Thank you for listening. Don’t forget to subscribe.
Keywords
natriuresis-guided therapy, echocardiography, vericiguat, symptomatic heart failure, heart failure with reduced ejection fraction, operator variability, artificial intelligence, urine biomarkers, loop diuretics, transthyretin amyloid cardiomyopathy, all-cause mortality, real-world evidence, vutrisiran, left ventricular mass, diuretic resistance, heart failure hospitalization, PUSH-A.H.F. study, H.E.L.I.O.S.-B trial, computed tomography, Chinese patients, acute decompensated heart failure, congestion, cardiovascular events.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Vutrisiran Reduces Mortality in A.T.T.R. C.M. 10/31/25 first appeared on Cardiology Today.
Article Links:
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. (ESC heart failure)
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study. (European journal of heart failure)
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. (European journal of heart failure)
Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation. (JACC. Cardiovascular imaging)
Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/
Featured Articles
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41163405
Summary: This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159496
Summary: study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159479
Summary: This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran’s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.
Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41165630
Summary: hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.
Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41166531
Summary: This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat’s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat’s performance in routine clinical practice, confirming its benefits in a broader patient context.
Transcript
Today’s date is October 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.
Article number two. Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-A.H.F. study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.
Article number three. Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The H.E.L.I.O.S.-B trial. This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran’s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.
Article number four. Fully Automatic A.I. hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.
Article number five. Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat’s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat’s performance in routine clinical practice, confirming its benefits in a broader patient context.
Thank you for listening. Don’t forget to subscribe.
Keywords
natriuresis-guided therapy, echocardiography, vericiguat, symptomatic heart failure, heart failure with reduced ejection fraction, operator variability, artificial intelligence, urine biomarkers, loop diuretics, transthyretin amyloid cardiomyopathy, all-cause mortality, real-world evidence, vutrisiran, left ventricular mass, diuretic resistance, heart failure hospitalization, PUSH-A.H.F. study, H.E.L.I.O.S.-B trial, computed tomography, Chinese patients, acute decompensated heart failure, congestion, cardiovascular events.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Vutrisiran Reduces Mortality in A.T.T.R. C.M. 10/31/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
Nup35 Controls Heart Remodeling 10/28/25
28/10/2025
In God we trust